Susvimo and VEGFxAng-2 bispecific antibody Vabysmo (faricimab) were intended to step into the breach and maintain Roche's franchise in eye disease. While Susvimo hit the buffers, Vabysmo has ...

Blockbuster Vabysmo has already been available in Europe ... recent approval in July this year when RVO was added to its EU label. Both the prefilled syringe and vials deliver faricimab, a ...

Approval of new drugs and label expansion of the existing ones should bode well for Roche. Drugs like Vabysmo, Ocrevus, ...

Roche has claimed a third approval from the FDA for its eye disease therapy Vabysmo – already its fastest-growing product – that could make it an option for hundreds of thousands of additional ...

eye drug Vabysmo and allergy treatment Xolair. Quarterly group revenues came in at 15.44 billion Swiss francs ($18.64 billion), slightly above average market expectations of about 15.4 billion ...